The Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo candidate.

Raina Biosciences Inc. (Raina), an mRNA technology and therapeutics company, has released data from its generative AI platform in Science. The data supports Raina's pioneering approach to mRNA design ...

Since the COVID-19 pandemic, mRNA vaccines have gained attention as a next-generation pharmaceutical technology. mRNA therapeutics work by delivering genetic instructions that enable cells to produce ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.

Messenger RNA (mRNA) therapeutics hold significant promise for the future of personalized cancer treatment, but persistent off-target effects and treatment-resistant tumor microenvironments have ...

ParcelBio's co-founders Chris Carlson, PhD (left), and David Weinberg, PhD (right) [ParcelBio] Biotechnology company ParcelBio said this week that it has raised $13 million in a seed financing round ...

HYDERABAD, India & SAN FRANCISCO--(BUSINESS WIRE)--PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein ...

CEPI has approved the advancement of the vaccine program following promising proof-of-concept results generated by Vaxxas in preclinical models, showing excellent thermostability and effective ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Raina Biosciences published data from its generative AI platform in a study, “Deep generative models design mRNA sequences with enhanced translational capacity and stability,” recently published in ...